



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: SAGAWA5

In re Application of:	)	Conf. No.:
SAGAWA et al.	)	Art Unit:
Appln. No.: 10/567,731	)	Examiner:
Filed: February 10, 2006	)	Washington, D.C.
For: METHODS OF DEGRADING	)	May 9, 2006
DsRNA AND SYNTHESIZING RNA)	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Randolph Building, Mail Stop Amendments  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application; and before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration

In re Appln. No. 10/567,731

by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:



Allen C. Yun  
Registration No. 37,971

ACY:pp  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202)628-5197  
Facsimile: (202)737-3528  
G:\BN\A\Aoyb\Sagawa5\Pto\2006-05-09 ids.doc



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 1

**Complete if Known**

Application Number	10/567,731
Filing Date	February 10, 2006
First Named Inventor	SAGAWA et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	SAGAWA5

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-2002/0162126 A1	10-31-2002	BEACH et al.	
	AB	US-6,479,260 B1	11-12-2002	TAKAYAMA et al.	
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AC	BAE et al., <i>Escherichia coli</i> CspA-family RNA chaperones are transcription antiterminators, <i>PNAS</i> , 97:(14)7784-7789 (2000)	✓
	AD	KREMER et al., Solution NMR structure of the cold-shock protein from the hyperthermophilic bacterium <i>Thermotoga maritima</i> , 268:2527-2539 (2001)	✓
	AE	MELEKHOVETS et al., Fusion with an RNA binding domain to confer target RNA specificity to an Rnase: design and engineering of Tat-Rnase H that specifically recognizes and cleaves HIV-1 RNA <i>in vitro</i> , <i>Nucleic Acids Research</i> , 24(10):1908-1912 (1996)	✓
	AF	PROVOST et al., Ribonuclease activity and RNA binding of recombinant human dicer, <i>The EMBO Journal</i> , 21(21):5864-5874 (2002)	
	AG	GUO et al., par-1, a gene required for establish polarity in <i>C. elegans</i> embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed, <i>Cell</i> , 81:611-620 (1995)	
	AH	FIRE et al., Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> , <i>Nature</i> , 391:806-811 (1998)	
	AI	BERNSTEIN et al., Role for a bidentate ribonuclease in the initiation step of RNA interference, <i>Nature</i> , 409(6818):363-366 (2001)	
	AJ	TABARA et al., The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DexH-Box helicase to direct RNAi in <i>C. elegans</i> , <i>Cell</i> , 109:861-871 (2002)	
	AK	ZHANG et al., Human dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP, <i>The EMBO Journal</i> , 21(21):5875-5885 (2002)	
	AL	MYERS et al., Recombinant dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing, <i>Nature Biotechnology</i> , 21:324-328 (2003)	
	AM	DONZÉ et al., RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase, <i>Nucleic Acids Research</i> , 30(10e46) (2002)	
	AN	WELKER et al., Cloning, overexpression, purification, and physicochemical characterization of a cold shock protein homology from the hyperthermophilic bacterium <i>Thermotoga maritima</i> , <i>Protein Science</i> , 8:394-403 (1999)	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.